Human prostate carcinomas initially regress after androgen ablation, but can eventually relapse into a hormoneindependent phenotype resistant to apoptosis. This resistance is associated with increased expression of antiapoptotic proteins such as Bcl-2.
Caspase proteases have been described as the central executioners of cell death. Their cleavage from the inactive pro-form to their active enzyme is a critical step in most types of apoptosis. We hypothesize that altered expression of pro-caspases may also contribute to prostate cancer resistance to apoptosis, and the mechanisms regulating expression of these caspases may have important implications in inducing or priming these cells for apoptosis. Diethylmaleate (DEM), a thiol-depleting agent, can induce apoptosis in both androgen-sensitive and insensitive prostate cancer cell lines which are caspase-3 dependent.
These studies aimed to determine if there is an alteration in pro-caspase 3 expression in normal, benign and malignant archived prostate sections and to investigate the role of DEM in increasing pro-caspase expression and apoptotic potential in prostate cancer cells.
Method
Specimens were obtained from 10 patients undergoing surgical resection of the prostate. Formalin-®xed, paraf®n-embedded sections were examined for pro-caspase 3 expression by immunohistochemical staining using a polyclonal goat anti-caspase 3 and avidin-biotin complex. Prostate sections were divided into: normal, benign prostatic hyperplasia (BPH) and malignant carcinoma, based on morphological appearance. The following grades were applied: 0 negative; 1 `1% weakly positive tumour cells; 2 multifocal aggregates of uniformly staining tumour cells; 3 diffuse positive staining throughout the tumour. Cultured PC3 cells were incubated with or without DEM (50 mM) and then treated with Fas (0.1 mgaml), cycloheximide (1 mgaml), etoposide (60 mM) and radiation (5Gy). Apoptosis was measured by propidium iodide incorporation at 3 days. Pro-caspase 3a8 and Bcl-2aBcl-x expression was assessed by western blotting over time.
Results
Pro-caspase 3 was expressed in 4a4 malignant sections and 6a6 BPH (graded between 2 and 3). Strong glandular basal membrane staining was observed in the BPH sections with all cells staining. Random cellular staining and delicate apical surface membrane staining was more obvious in the malignant section. Low-dose DEM primed PC3 cells to Fas antibody, etoposide and radiation-mediated apoptosis without inducing apoptosis alone (see Table 1 ). Similar effects were found for LNCaP cells. This priming effect for apoptosis was independent of any changes in intracellular levels of GSH or GST and correlated with an upregulation of pro-caspase 3 and 8 expression. There were also corresponding decreases in Bcl-2aBcl-x expression.
Conclusion
Pro-caspase 3 expression occurs in both benign and malignant prostate tissue sections, but more diffuse staining was observed in the malignant tissue. This preliminary study indicates that pro-caspase 3 may have altered expression and localization within malignant cells, which may interfere with the activation of the caspase cascade and cell death. Low-dose DEM which primes prostate cancer cells for increased pro-caspase expression and apoptosis may have therapeutic implications. Altering pro-apoptotic pathways within the cell is a novel approach to the treatment of prostate cancer. 
